Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Will Differentiate To Serve A Different World

Executive Summary

A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.

You may also be interested in...



Global Top Three Trade Places As Going Gets Tough, Especially In The US

Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.

US And Japan Cause A Slip In Value-Added Market

Difficulties in the US and Japan have stalled growth in the global value-added medicines market. But a coming wave of digital therapeutics promises to revive the market.

Sandoz Head Francis To Leave Amid Move Towards Autonomy

Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB139924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel